331 related articles for article (PubMed ID: 32353461)
1. Enhanced Susceptibility of PINK1 Knockout Rats to α-Synuclein Fibrils.
Creed RB; Goldberg MS
Neuroscience; 2020 Jun; 437():64-75. PubMed ID: 32353461
[TBL] [Abstract][Full Text] [Related]
2. Analysis of hemisphere-dependent effects of unilateral intrastriatal injection of α-synuclein pre-formed fibrils on mitochondrial protein levels, dynamics, and function.
Creed RB; Memon AA; Komaragiri SP; Barodia SK; Goldberg MS
Acta Neuropathol Commun; 2022 May; 10(1):78. PubMed ID: 35606853
[TBL] [Abstract][Full Text] [Related]
3. Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice.
Oliveras-Salvá M; Macchi F; Coessens V; Deleersnijder A; Gérard M; Van der Perren A; Van den Haute C; Baekelandt V
Neurobiol Aging; 2014 Nov; 35(11):2625-2636. PubMed ID: 25037286
[TBL] [Abstract][Full Text] [Related]
4. PTEN-Induced Putative Kinase 1 Dysfunction Accelerates Synucleinopathy.
Nguyen TT; Kim YJ; Lai TT; Nguyen PT; Koh YH; Nguyen LTN; Ma HI; Kim YE
J Parkinsons Dis; 2022; 12(4):1201-1217. PubMed ID: 35253778
[TBL] [Abstract][Full Text] [Related]
5. Increased glutamate transmission onto dorsal striatum spiny projection neurons in Pink1 knockout rats.
Creed RB; Roberts RC; Farmer CB; McMahon LL; Goldberg MS
Neurobiol Dis; 2021 Mar; 150():105246. PubMed ID: 33387634
[TBL] [Abstract][Full Text] [Related]
6. Analysis of α-Synuclein Pathology in PINK1 Knockout Rat Brains.
Creed RB; Goldberg MS
Front Neurosci; 2018; 12():1034. PubMed ID: 30686993
[TBL] [Abstract][Full Text] [Related]
7. Dose-related biphasic effect of the Parkinson's disease neurotoxin MPTP, on the spread, accumulation, and toxicity of α-synuclein.
Merghani MM; Ardah MT; Al Shamsi M; Kitada T; Haque ME
Neurotoxicology; 2021 May; 84():41-52. PubMed ID: 33549656
[TBL] [Abstract][Full Text] [Related]
8. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
[TBL] [Abstract][Full Text] [Related]
9. Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.
Duffy MF; Collier TJ; Patterson JR; Kemp CJ; Luk KC; Tansey MG; Paumier KL; Kanaan NM; Fischer DL; Polinski NK; Barth OL; Howe JW; Vaikath NN; Majbour NK; El-Agnaf OMA; Sortwell CE
J Neuroinflammation; 2018 May; 15(1):129. PubMed ID: 29716614
[TBL] [Abstract][Full Text] [Related]
10. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
[TBL] [Abstract][Full Text] [Related]
11. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
[TBL] [Abstract][Full Text] [Related]
12. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
[TBL] [Abstract][Full Text] [Related]
13. Loss of One Engrailed1 Allele Enhances Induced α-Synucleinopathy.
Chatterjee D; Sanchez DS; Quansah E; Rey NL; George S; Becker K; Madaj Z; Steiner JA; Ma J; Escobar Galvis ML; Kordower JH; Brundin P
J Parkinsons Dis; 2019; 9(2):315-326. PubMed ID: 30932894
[TBL] [Abstract][Full Text] [Related]
14. 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.
Underwood R; Gannon M; Pathak A; Kapa N; Chandra S; Klop A; Yacoubian TA
Acta Neuropathol Commun; 2021 Jan; 9(1):13. PubMed ID: 33413679
[TBL] [Abstract][Full Text] [Related]
15. Long-term oral kinetin does not protect against α-synuclein-induced neurodegeneration in rodent models of Parkinson's disease.
Orr AL; Rutaganira FU; de Roulet D; Huang EJ; Hertz NT; Shokat KM; Nakamura K
Neurochem Int; 2017 Oct; 109():106-116. PubMed ID: 28434973
[TBL] [Abstract][Full Text] [Related]
16. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
17. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration.
Soria FN; Engeln M; Martinez-Vicente M; Glangetas C; López-González MJ; Dovero S; Dehay B; Normand E; Vila M; Favereaux A; Georges F; Lo Bianco C; Bezard E; Fernagut PO
Hum Mol Genet; 2017 Jul; 26(14):2603-2615. PubMed ID: 28520872
[TBL] [Abstract][Full Text] [Related]
18. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
19. Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.
Patterson JR; Duffy MF; Kemp CJ; Howe JW; Collier TJ; Stoll AC; Miller KM; Patel P; Levine N; Moore DJ; Luk KC; Fleming SM; Kanaan NM; Paumier KL; El-Agnaf OMA; Sortwell CE
Neurobiol Dis; 2019 Oct; 130():104525. PubMed ID: 31276792
[TBL] [Abstract][Full Text] [Related]
20. New Developments in Genetic rat models of Parkinson's Disease.
Creed RB; Goldberg MS
Mov Disord; 2018 May; 33(5):717-729. PubMed ID: 29418019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
